[go: up one dir, main page]

AR082688A1 - Uso de aglomerantes para preparar formulaciones estables al almacenamiento - Google Patents

Uso de aglomerantes para preparar formulaciones estables al almacenamiento

Info

Publication number
AR082688A1
AR082688A1 ARP110102958A ARP110102958A AR082688A1 AR 082688 A1 AR082688 A1 AR 082688A1 AR P110102958 A ARP110102958 A AR P110102958A AR P110102958 A ARP110102958 A AR P110102958A AR 082688 A1 AR082688 A1 AR 082688A1
Authority
AR
Argentina
Prior art keywords
storage
derivative
pharmaceutically acceptable
acceptable salt
binders
Prior art date
Application number
ARP110102958A
Other languages
English (en)
Inventor
Derek Allan Prater
Christof Spitzley
Gerhard Josef Heun
Udo Hahn
Christian Leuner
Alexander Schtz
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43382375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR082688(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of AR082688A1 publication Critical patent/AR082688A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica oral de liberación prolongada, caracterizada porque comprende al menos: a) al menos un material de liberación prolongada; b) al menos oxicodona o una sal o derivado farmacéuticamente aceptable de la misma y naloxona. o una sal o su derivado farmacéuticamente aceptable; y donde c) la composición farmacéutica después del almacenamiento bajo condiciones de estrés tiene menos que el 4% del total de sustancias relacionadas con oxicodona o una sal o derivado farmacéuticamente aceptable de la misma y/o relacionadas con naloxona o una sal o derivado farmacéuticamente aceptable de la misma.
ARP110102958A 2010-08-13 2011-08-15 Uso de aglomerantes para preparar formulaciones estables al almacenamiento AR082688A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37334410P 2010-08-13 2010-08-13
EP10172759 2010-08-13

Publications (1)

Publication Number Publication Date
AR082688A1 true AR082688A1 (es) 2012-12-26

Family

ID=43382375

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102958A AR082688A1 (es) 2010-08-13 2011-08-15 Uso de aglomerantes para preparar formulaciones estables al almacenamiento

Country Status (29)

Country Link
US (2) US20130245054A1 (es)
EP (2) EP3505162A1 (es)
JP (1) JP6007176B2 (es)
KR (1) KR101518143B1 (es)
CN (1) CN103118668B (es)
AR (1) AR082688A1 (es)
AU (1) AU2011288413B2 (es)
BR (1) BR112013003150B1 (es)
CA (1) CA2805974C (es)
CH (1) CH705678B1 (es)
CL (1) CL2013000444A1 (es)
CO (1) CO6680640A2 (es)
DE (1) DE112011102708T5 (es)
DK (1) DK178702B1 (es)
EC (1) ECSP13012467A (es)
ES (1) ES2409069B2 (es)
GB (1) GB2495676B (es)
MX (1) MX355644B (es)
MY (1) MY165149A (es)
NO (1) NO20130366A1 (es)
NZ (1) NZ606123A (es)
PE (1) PE20131101A1 (es)
PH (1) PH12013500172A1 (es)
RU (1) RU2572695C2 (es)
SE (1) SE537698C2 (es)
SG (1) SG187678A1 (es)
SI (1) SI2603205T1 (es)
TW (1) TWI469781B (es)
WO (1) WO2012020097A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2412409T3 (es) 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US20030065002A1 (en) 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
EP1492505B1 (en) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
BRPI1006186A2 (pt) 2009-03-10 2016-08-23 Euro Celtique Sa composições farmaceuticas de liberação imediata compreedendo oxicodona e naloxona
MX344846B (es) 2010-05-10 2017-01-10 Euro-Celtique S A * Combinacion de granulos cargados activos con activos adicionales.
AU2011252040C1 (en) 2010-05-10 2015-04-02 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
US20140271893A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Coated phenylephrine particles and use thereof in pharmaceutical formulations
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
EP3068397A1 (en) 2013-11-13 2016-09-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CA2964628A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3229785A2 (de) * 2014-12-08 2017-10-18 Develco Pharma Schweiz AG Naloxon-monopräparat und mehrschichttablette
WO2018055199A1 (en) 2016-09-26 2018-03-29 Euro-Celtique S.A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
AU2018252153A1 (en) * 2017-04-13 2019-11-07 Jean Paul Remon Xanthohumol-based compositions
CN111686094A (zh) * 2020-07-13 2020-09-22 云南民族大学 一种脂肪醇类化合物在制备通便药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3581428D1 (de) 1984-06-13 1991-02-28 Roehm Gmbh Verfahren zum ueberziehen von arzneiformen.
EP1442745A1 (en) * 1993-10-07 2004-08-04 Euro-Celtique Orally administrable opioid formulations having extended duration of effect
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
JP4848558B2 (ja) * 2001-05-08 2011-12-28 トーアエイヨー株式会社 塩酸メトホルミン含有速放性錠剤
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
JP2003160487A (ja) * 2001-11-20 2003-06-03 Ohara Yakuhin Kogyo Kk プラバスタチンナトリウム含有錠剤およびその製造法
EP1492505B1 (en) * 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
DE102005048293A1 (de) * 2005-10-08 2007-04-12 Sanofi-Aventis Deutschland Gmbh Retardformulierung für Pralnacasan
KR100753480B1 (ko) * 2006-01-27 2007-08-31 씨제이 주식회사 잘토프로펜 함유 서방성 정제 및 그 제조방법
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
JP2009298707A (ja) * 2008-06-11 2009-12-24 Ohara Yakuhin Kogyo Kk 粒子加工方法
EP2448406B1 (en) * 2009-02-26 2016-04-20 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use

Also Published As

Publication number Publication date
MX2013001757A (es) 2013-05-06
BR112013003150B1 (pt) 2022-01-18
SG187678A1 (en) 2013-03-28
SE1350286A1 (sv) 2013-03-21
WO2012020097A2 (en) 2012-02-16
CH705678B1 (de) 2016-03-15
PE20131101A1 (es) 2013-09-23
JP6007176B2 (ja) 2016-10-12
MX355644B (es) 2018-04-26
AU2011288413A1 (en) 2013-02-21
DE112011102708T5 (de) 2013-05-29
GB2495676B (en) 2018-08-22
GB2495676A (en) 2013-04-17
EP3505162A1 (en) 2019-07-03
SE537698C2 (sv) 2015-09-29
ECSP13012467A (es) 2013-03-28
DK178702B1 (en) 2016-11-21
TWI469781B (zh) 2015-01-21
US20160095853A1 (en) 2016-04-07
RU2013110820A (ru) 2014-09-20
PH12013500172A1 (en) 2022-10-24
AU2011288413B2 (en) 2014-05-22
RU2572695C2 (ru) 2016-01-20
CN103118668A (zh) 2013-05-22
DK201370075A (en) 2013-02-13
CL2013000444A1 (es) 2013-08-23
TW201228662A (en) 2012-07-16
EP2603205A2 (en) 2013-06-19
CN103118668B (zh) 2016-07-06
NZ606123A (en) 2015-03-27
KR101518143B1 (ko) 2015-05-06
US20130245054A1 (en) 2013-09-19
MY165149A (en) 2018-02-28
CA2805974A1 (en) 2012-02-16
GB201301916D0 (en) 2013-03-20
EP2603205B1 (en) 2018-10-03
ES2409069R1 (es) 2013-08-30
SI2603205T1 (sl) 2019-02-28
WO2012020097A3 (en) 2012-05-03
CO6680640A2 (es) 2013-05-31
BR112013003150A2 (pt) 2020-09-08
ES2409069B2 (es) 2014-07-17
CA2805974C (en) 2019-11-26
ES2409069A2 (es) 2013-06-24
JP2013533303A (ja) 2013-08-22
KR20130083903A (ko) 2013-07-23
NO20130366A1 (no) 2013-04-29

Similar Documents

Publication Publication Date Title
AR082688A1 (es) Uso de aglomerantes para preparar formulaciones estables al almacenamiento
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
CL2013000801A1 (es) Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion
BR112012016398A2 (pt) Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
CL2008001002A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
CL2007003108A1 (es) Compuestos derivados de n-hidroxiamida sustituida con heterociclos, inhibidores de histona desacetilasa; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una enfermedad del grupo que consiste en enfermedad de huntington,
AR077629A1 (es) Mimetico de smac
CL2008001003A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
CL2016001424A1 (es) Composiciones de liberación retardada de lionaclotida
ES2478264T3 (es) Glicerosomas y uso de estos en preparaciones farmacéuticas y cosméticas para aplicación tópica
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
CL2011000214A1 (es) Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona.
CL2012000319A1 (es) Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística.
CR11418A (es) Trans-clomifeno para el sindrome metabolico
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
CL2013000098A1 (es) Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso.
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
CL2016000510A1 (es) Composiciones para comprimidos bucodispersables que contienen corticosteroides para esofagitis eosinofílica
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
CL2014000552A1 (es) Uso de 4,4´-[fluoro-(1h-1,2,4-triazol-1-il)metileno]bisbenzonitrilo para el tratamiento del hipogonadismo y composicion farmaceutica oral que comprende al compuesto y kit farmaceutico que comprende a la composicion.
AR090975A1 (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida

Legal Events

Date Code Title Description
FC Refusal